Wallaby Medical acquires Phenox

Together, the companies aim to become the global market leader in treatments for neurovascular diseases such as strokes.

The medical technology group Wallaby Medical has acquired the Bochum-based start-up Phenox for 500 million euros. The Phenox offshoot Femtos will also belong to Wallaby Medical in the future. Together, the companies aim to become global market leaders in the treatment of neurovascular diseases.

Phenox has been in existence since 2005 and has developed various treatment options for strokes and aneurysms. Customers in more than 45 countries now use Phenox's products. Its offshoot, Femtos, develops neurovascular devices as well as implantable devices. In doing so, the company makes use of laser technology.

"This transaction will allow Phenox's technology to be further developed with Wallaby's strong resources, while opening up new markets for Phenox's products," says Phenox founder Hermann Monstadt.

Wallaby Medical has its main locations in the U.S. and China. The two companies had already been working together as strategic partners since 2019. In the joint company, Wallaby Medical CEO Michael Alper will take over as managing director. Monstadt will become managing director at Phenox. The money for the acquisition came from a Series D financing round by Wallaby Medical.